The Clinical Trials Initiative seeks to expand the availability of clinical trials to assist patients and researchers, improve health outcomes, and advance our knowledge of neurodegenerative diseases. Researchers utilize clinical trials to develop groundbreaking new therapies for and a deeper understanding of neurodegenerative diseases, many of which have only limited treatment options and for which we are only beginning to understand the etiology. Patients also benefit from participation in clinical trials by being recipients of interventions, such as medications, therapies, etc., which can help their condition. Neurodegenerative diseases, such as Alzheimer’s disease (AD), frontotemporal lobar degeneration, Lewy body disease, etc., are a growing public health concern particularly as the population ages. Neuroscientists are actively seeking the causes, treatment of, and prevention of many diseases. Improving diagnostic tools, ranging from blood and cerebrospinal fluid samples to radiographic imaging, is another important feature of this type of work. Collaborating with national organizations, The National Institutes of Health, and pharmaceutical companies, academic clinicians here at Vanderbilt can unite our passion for research with scientists around the country to provide opportunities for patients to be involved in cutting-edge research in the hopes of not only benefitting current patients, but the health of future generations.
To see if you or a loved one is eligible for an upcoming clinical trial, please fill out a brief survey using the following link:
- Alzheimer’s Disease Cooperative Study (ADCS)
- Angela Jefferson, PhD / Professor of Neurology at Vanderbilt University Medical Center
- Paul Newhouse, MD / Professor of Psychiatry and Behavioral Sciences at Vanderbilt University Medical Center
- Katherine Gifford, PsyD / Assistant Professor of Neurology at Vanderbilt University Medical Center
- James Eaton, MD / Assistant Professor of Neurology at Vanderbilt University Medical Center